Zhejiang Medicine Co., Ltd. (600216.SS) announced a profit for full year that Dropped, from the same period last year
The company's bottom line totaled RMB873.380 million, or RMB0.91 per share. This compares with RMB1.160 billion, or RMB1.21 per share, last year.
The company's revenue for the period fell 5.3% to RMB8.880 billion from RMB9.375 billion last year.
Zhejiang Medicine Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB873.380 Mln. vs. RMB1.160 Bln. last year.-EPS: RMB0.91 vs. RMB1.21 last year.-Revenue: RMB8.880 Bln vs. RMB9.375 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.